Roth MKMはCervoMedの価格を15ドルに倍増し,神経障害治療の潜在力を強調する. Roth MKM doubles CervoMed's price target to $15.00, highlighting potential in neurologic disorder treatments.

Rosth MKMは,バイオテクノロジー企業 CervoMed (NASDAQ: CRVO) の価格を"Buy"の評価で7.00ドルから15.00ドルまで上げた. Roth MKM raised its price target for biotech company CervoMed (NASDAQ: CRVO) to $15.00, up from $7.00, with a "buy" rating. MarketBeat.comは平均"中程度の買い"の評価と33.14ドルのコンセンサス目標を報告しています. MarketBeat.com reports an average "Moderate Buy" rating and consensus target of $33.14. CervoMedは,老齢に関連した神経障害の治療に焦点をあて,鉛剤やネフラパディモなどを用おり,レイイの身体やアルツハイマーなどの痴呆症の治療を目的としている. CervoMed focuses on treating age-related neurologic disorders, with its lead drug, neflamapimod, targeting conditions like dementia with Lewy bodies and Alzheimer's. 火曜日には,株式は2.03ドルに下げ,177,420株が取引された. On Tuesday, the stock traded down to $2.03, with 177,420 shares traded.